CD68 and prostate cancer: Forty patients were analyzed after radical prostatectomy and 35 after androgen deprivation therapy. In androgen deprivation treated patients, high number of CD56 cells was associated with a lower risk of prostate cancer progression (P = 0.044), while a high density of CD68 was related to an increased risk of biochemical recurrence (P = 0.011)